


Setrobuvir

Chemical Properties

CAS No. :	1071517-39-9
Formula:	C ₂₅ H ₂₅ FN ₄ O ₆ S ₂
Molecular Weight:	560.62
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Setrobuvir (ANA-598) is an orally active, highly selective non-nucleoside HCV NS5B polymerase inhibitor that inhibits new RNA synthesis and primer extension, with IC ₅₀ values ranging from 4 to 5 nM. Setrobuvir exhibits high binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp. Setrobuvir is suitable for Antiviral drugs studies.
Targets(IC50)	HCV Protease,DNA/RNA Synthesis,SARS-CoV
In vivo	Setrobuvir (200, 400, and 800 mg) BID were -2.1, -2.2, and -2.9 log ₁₀ IU/mL, respectively (vs ≤0.1 log ₁₀ IU/mL with placebo).[3]

Solubility Information

Solubility	DMSO: 252.5 mg/mL (450.39 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7837 mL	8.9187 mL	17.8374 mL
5 mM	0.3567 mL	1.7837 mL	3.5675 mL
10 mM	0.1784 mL	0.8919 mL	1.7837 mL
50 mM	0.0357 mL	0.1784 mL	0.3567 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. *J Biomol Struct Dyn*. 2020;1-9.
- Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. *Antimicrob Agents Chemother*. 2012;56(2):830-837.
- Mallalieu NL, et al. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor. *Clin Ther*. 2014 ; 36(12):2047-2063.
- Eltahla AA, et al. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. *Antimicrob Agents Chemother*. 2014 ; 58(12):7215-7224.
- De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. *Biochem Pharmacol*. 2014 ; 89(4):441-452.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481